GlaxoSmithKline News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

05.07.24	Brazil and Thailand become first malaria-endemic countries to launch new single-dose radical cure medicine to prevent the relapse of Plasmodium vivax malaria (EN, GlaxoSmithKline)
03.07.24	GSK and CureVac to restructure collaboration into new licensing agreement (EN, GlaxoSmithKline)
03.07.24	Curevac streicht fast jeden dritten Job - Milliardendeal mit GSK (AWP)
03.07.24	Curevac baut um: GSK zahlt bis zu 1,4 Milliarden für Grippe-, Covid-Impfstoffe (AWP)
28.06.24	Statement: Zantac (ranitidine) litigation - Gross case (EN, GlaxoSmithKline)
26.06.24	Statement: US Centers for Disease Control and Prevention’s Advisory Committee on Immunisation Practices updates recommendations on adult RSV vaccines ahead of the next season (EN, GlaxoSmithKline)
24.06.24	Jemperli (dostarlimab) plus chemotherapy application accepted for review by the European Medicines Agency to expand use to all patients with primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
10.06.24	Statement: Zantac (ranitidine) litigation - Kasza case (EN, GlaxoSmithKline)
08.06.24	US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk (Businesswire)
07.06.24	US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
06.06.24	GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies (EN, GlaxoSmithKline)
03.06.24	GSK-, Sanofi- und Pfizer-Aktien: Pharmatitel geraten nach Urteil in den USA unter Druck (finanzen.ch) Mehrere grosse Pharmakonzerne müssen sich wegen möglicher Krebsrisiken des Medikaments Zantac in den USA vor Gericht verantworten.» mehr
03.06.24	Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer (EN, GlaxoSmithKline)
03.06.24	Pharmakonzerne müssen sich Zantac-Klagen stellen - Kursrutsch bei GSK (AWP)
03.06.24	Pharmakonzerne müssen sich Zantac-Klagen stellen - Kursrutsch bei GSK (AWP)
02.06.24	Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
01.06.24	Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling (EN, GlaxoSmithKline)
23.05.24	Statement: Zantac (ranitidine) litigation - Valadez and Williams cases (EN, GlaxoSmithKline)
21.05.24	GSK announces positive results from phase III severe asthma trials of depemokimab (EN, GlaxoSmithKline)
16.05.24	GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR) (EN, GlaxoSmithKline)
01.05.24	Pharmahersteller GSK erhöht Gewinnziel für 2024 (AWP)
01.05.24	GSK makes a strong start to 2024 with improving outlook for the year (EN, GlaxoSmithKline)
18.04.24	Brexit-Folgen verschärfen laut Studie britische Arzneimittelknappheit (AWP)
17.04.24	EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments (EN, GlaxoSmithKline)
17.04.24	New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade (EN, GlaxoSmithKline)
16.04.24	GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA (EN, GlaxoSmithKline)
18.03.24	CureVac-Aktie fällt: Impfstoffhersteller CureVac will am Personal sparen (AWP) Das Tübinger Biotech-Unternehmen CureVac will über ein Freiwilligenprogramm rund 150 Stellen streichen.» mehr
16.03.24	Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
07.03.24	GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise (Businesswire)
07.03.24	GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
04.03.24	ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses (EN, GlaxoSmithKline)
29.02.24	GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director (EN, GlaxoSmithKline)
29.02.24	Statement: Zantac (ranitidine) litigation (EN, GlaxoSmithKline)
28.02.24	ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV (EN, GlaxoSmithKline)
26.02.24	GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC) (EN, GlaxoSmithKline)
15.02.24	GSK completes acquisition of Aiolos Bio (EN, GlaxoSmithKline)
12.02.24	GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B (EN, GlaxoSmithKline)
06.02.24	GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
06.02.24	GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk (Businesswire)
06.02.24	GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration (EN, GlaxoSmithKline)
05.02.24	DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
01.02.24	Statement: Zantac (ranitidine) litigation (EN, GlaxoSmithKline)
31.01.24	Pharmahersteller GSK will auch 2024 mehr verdienen - Aktie legt zu (AWP)
31.01.24	Pharmahersteller GSK will auch 2024 mehr verdienen - optimistischer für Zukunft (AWP)
31.01.24	GSK delivers strong 2023 performance and upgrades growth outlooks (EN, GlaxoSmithKline)
29.01.24	GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
29.01.24	European Commission authorises GSK’s Omjjara (momelotinib) (EN, GlaxoSmithKline)
10.01.24	Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype (EN, GlaxoSmithKline)
09.01.24	GSK enters agreement to acquire Aiolos Bio (EN, GlaxoSmithKline)
20.12.23	GSK enters exclusive license agreement with Hansoh for HS-20093 (EN, GlaxoSmithKline)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	534.20	0.60 %	K V
Sonova Hldg	305.30	0.23 %	K V
Alcon	77.70	0.10 %	K V
Roche Hldg G	251.60	0.08 %	K V
Novartis	91.92	-0.01 %	K V
UBS Group	27.53	-0.83 %	K V
CieFinRichemont	121.25	-0.90 %	K V
ABB	49.02	-1.05 %	K V
Sika	225.00	-1.57 %	K V
Logitech Intl	70.46	-2.11 %	K V

mehr

27.07.22		GSK-Aktie gefragt: GlaxoSmithKline hebt Jahresziele an
18.07.22		Haleon-Aktie etwas tiefer: GSK-Abspaltung Haleon wird erstmals in London gehandelt
23.06.22		GSK-Aktie in Grün: GSK will Infektionskrankheiten in armen Ländern bekämpfen
06.06.22		GlaxoSmithKline-Aktie stabil: US-Zulassung für Impfstoff Priorix erhalten
01.06.22		GSK-Aktie schwach: GlaxoSmithKline will Konsumentensparte Mitte Juli an die Börse bringen - Pfizer steigt aus
31.05.22		GSK-Aktie legt leicht zu: GlaxoSmithKline erwirbt Biopharma-Spezialisten in Milliardendeal
27.04.22		GSK-Aktie höher: GlaxoSmithKline übertrifft Gewinnerwartungen
27.04.22		Ausblick: GlaxoSmithKline gewährt Anlegern Blick in die Bücher